December 15, 2022 – Teleflex announced that 400,000 patients have now been treated with the UroLift® System, a safe, effective and minimally invasive treatment option for benign prostatic hyperplasia (BPH) or enlarged prostate. The UroLift® System is the number one minimally invasive BPH procedure chosen by urologists and their patients in the U.S. The 5-year L.I.F.T. study results demonstrate UroLift® System durability with a surgical retreatment rate of about 2-3% per year and 13.6% total over 5 years.
BPH is a non-cancerous enlargement of the prostate, occurring naturally as men age, which can cause urinary problems, decrease quality of life, and interrupt sleep. More than 14 million men in the U.S. seek treatment for the condition every year.
Teleflex recently conducted a survey of 1,000 U.S. men aged 45+ who are experiencing BPH symptoms to better understand the treatment journey and patient behavior surrounding BPH.
Key findings include:
- 70% of men surveyed, who were as young as 45, indicated medications were recommended as at least one option for treating BPH.
- Nearly half of the respondents on medication (44%) are interested in alternative treatment options.